Skip to content
2000
Volume 15, Issue 5
  • ISSN: 2468-1873
  • E-ISSN: 2468-1881

Abstract

Skin cancer is one of the most common types of cancer globally, with melanoma and non-melanoma being the two primary forms. Melanoma tends to be less frequent but more dangerous, while non-melanoma types, including squamous and basal cell carcinoma, are more prevalent. Caucasian populations are at a higher risk of developing skin cancer due to their skin's susceptibility to ultraviolet (UV) radiation. According to recent data, skin cancer ranks as the seventeenth most common cancer worldwide. An emerging approach to treating skin conditions, including skin cancer, is using niosomes, an advanced drug delivery system. Niosomes are vesicles made from non-ionic surfactants, stabilized by cholesterol, that encapsulate drugs. They have gained prominence because they address several issues related to traditional topical treatments, such as poor solubility, instability, low bioavailability, and rapid drug breakdown. This review article focuses on the use of niosomes in dermatology, particularly for drug delivery through the skin. Niosomes offer several distinct advantages, making them an ideal choice for topical drug delivery. Their unique structure allows them to transport both water-soluble and fat-soluble drugs effectively. Additionally, they enhance drug permeation through the skin, improve drug stability, and allow for extended drug release. These properties make niosomes a valuable tool in clinical settings, providing potential benefits for a range of skin-related therapies. With their growing popularity, niosomes are shaping the future of innovative and more efficient topical drug delivery methods.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnanom/10.2174/0124681873335092250115022230
2025-01-28
2025-12-06

  • From This Site

    /content/journals/cnanom/10.2174/0124681873335092250115022230
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ShinuP. NairA.B. KumariB. JacobS. KumarM. TiwariA. TiwariV. VenugopalaK.N. AttimaradM. NagarajaS. Recent advances and appropriate use of niosomes for the treatment of skin cancer.Indian J. Pharmaceut. Educ. Res.202256410.5530/ijper.56.4.170
     [Google Scholar]
  2. BharathA. TurnerR. Impact of climate change on skin cancer.J. R. Soc. Med.2009102621521810.1258/jrsm.2009.08026119531614
     [Google Scholar]
  3. CoronaR. DogliottiE. D’ErricoM. SeraF. IavaroneI. BalivaG. ChinniL.M. GobelloT. MazzantiC. PudduP. PasquiniP. Risk factors for basal cell carcinoma in a Mediterranean population: Role of recreational sun exposure early in life.Arch. Dermatol.200113791162116810.1001/archderm.137.9.116211559211
     [Google Scholar]
  4. TilliC.M.L.J. Van SteenselM.A.M. KrekelsG.A.M. NeumannH.A.M. RamaekersF.C.S. Molecular aetiology and pathogenesis of basal cell carcinoma.Br. J. Dermatol.200515261108112410.1111/j.1365‑2133.2005.06587.x15948971
     [Google Scholar]
  5. ZieglerA. JonasonA.S. LeffelltD.J. SimonJ.A. SharmaH.W. KimmelmanJ. RemingtonL. JacksT. BrashD.E. Sunburn and p53 in the onset of skin cancer.Nature1994372650877377610.1038/372773a07997263
     [Google Scholar]
  6. StaplesM.P. ElwoodM. BurtonR.C. WilliamsJ.L. MarksR. GilesG.G. Non-melanoma skin cancer in Australia: The 2002 national survey and trends since 1985.Med. J. Aust.2006184161010.5694/j.1326‑5377.2006.tb00086.x16398622
     [Google Scholar]
  7. WelchH.G. WoloshinS. SchwartzL.M. Skin biopsy rates and incidence of melanoma: Population based ecological study.BMJ2005331751548110.1136/bmj.38516.649537.E016081427
     [Google Scholar]
  8. LeeJ.A.H. ScottoJ. Melanoma: Linked temporal and latitude changes in the United States.Cancer Causes Control19934541341810.1007/BF000508598218872
     [Google Scholar]
  9. AutierP. Perspectives in melanoma prevention: The case of sunbeds.Eur. J. Cancer200440162367237610.1016/j.ejca.2004.07.01815519507
     [Google Scholar]
  10. WhitmoreS.E. MorisonW.L. Melanoma after PUVA therapy for psoriasis.N. Engl. J. Med.1997337750250310.1056/NEJM1997081433707169254340
     [Google Scholar]
  11. World Health Organization. Search result.2024Available from:https://www.who.int/home/search-results?indexCatalogue=genericsearchindex1&searchQuery=skin%20cancer&wordsMode=AnyWord(accessed on 12-11-2024).
  12. SaraiyaM. GlanzK. BrissP.A. NicholsP. WhiteC. DasD. SmithS.J. TannorB. HutchinsonA.B. WilsonK.M. GandhiN. LeeN.C. RimerB. CoatesR.C. KernerJ.F. HiattR.A. BufflerP. RochesterP. Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation.Am. J. Prev. Med.200427542246610.1016/j.amepre.2004.08.00915556744
     [Google Scholar]
  13. CollinsS.A. ThompsonS.H. What are we feeding our inmates?J. Correct. Health Care201218321021810.1177/107834581244487522553283
     [Google Scholar]
  14. AslanÖ. The United States and Military Coups in Turkey and PakistanSpringer201810.1007/978‑3‑319‑66011‑0_5
     [Google Scholar]
  15. DilsizianS.E. SiegelE.L. Artificial intelligence in medicine and cardiac imaging: harnessing big data and advanced computing to provide personalized medical diagnosis and treatment.Curr. Cardiol. Rep.201416144110.1007/s11886‑013‑0441‑824338557
     [Google Scholar]
  16. Gadeliya GoodsonA. GrossmanD. Strategies for early melanoma detection: Approaches to the patient with nevi.J. Am. Acad. Dermatol.200960571973510.1016/j.jaad.2008.10.06519389517
     [Google Scholar]
  17. SeyfriedT.N. HuysentruytL.C. On the origin of cancer metastasis.Crit. Rev. Oncog.2013181-2437310.1615/CritRevOncog.v18.i1‑2.40
     [Google Scholar]
  18. Le ClairM.Z. CockburnM.G. Tanning bed use and melanoma: Establishing risk and improving prevention interventions.Prev. Med. Rep.2016313914410.1016/j.pmedr.2015.11.01627419006
     [Google Scholar]
  19. ChanduV.P. ArunachalamA. JeganathS. YaminiK. TharanginiK. ChaitanyaG. Niosomes: a novel drug delivery system.Int. J. Novel Trends Pharm. Sci.2012212531https://www.scienztech.org/index.php/ijntps/article/view/58
     [Google Scholar]
  20. KhandareJ.N. MadhaviG. TamhankarB.M. Niosomes-novel drug delivery system.Eastern Pharmacist.1994376110.5281/zenodo.10850135
     [Google Scholar]
  21. BaillieA.J. FlorenceA.T. HumeL.R. MuirheadG.T. RogersonA. The preparation and properties of niosomes—Non-ionic surfactant vesicles.J. Pharm. Pharmacol.1985371286386810.1111/j.2042‑7158.1985.tb04990.x2868092
     [Google Scholar]
  22. TalegaonkarS. MishraP.R. KharR.K. BijuS.S. Vesicular systems: An overview.Indian J. Pharm. Sci.200668214110.4103/0250‑474X.25707
     [Google Scholar]
  23. UchegbuI.F. VyasS.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery.Int. J. Pharm.19981721-2337010.1016/S0378‑5173(98)00169‑0
     [Google Scholar]
  24. MalhotraM. JainN.K. Niosomes as drug carriers.Indian J. Pharm. Sci.19945824146
     [Google Scholar]
  25. AlsarraI.A. BoselaA.A. AhmedS.M. MahrousG.M. Proniosomes as a drug carrier for transdermal delivery of ketorolac.Eur. J. Pharm. Biopharm.200559348549010.1016/j.ejpb.2004.09.00615760729
     [Google Scholar]
  26. SharmaR. DuaJ.S. PrasadD.N. HiraS, Monika. Advancement in novel drug delivery system: niosomes.J. Drug Deliv. Ther.201993-s995100110.22270/jddt.v9i3‑s.2931
     [Google Scholar]
  27. MakeshwarK.B. WasankarS.R. Niosome: A novel drug delivery system.Asian J. Pharmaceut. Res.201331569110.5958/2231–5691
     [Google Scholar]
  28. KatareR. GuptaP.N. MahorS. RawatA. KhatriK. KatareY. PandaA.K. VyasS.P. Development of polysaccharide-capped niosomes for oral immunization of tetanus toxoid.J. Drug Deliv. Sci. Technol.200616316717210.1016/S1773‑2247(06)50031‑0
     [Google Scholar]
  29. ArulJ. ShanmuganathanS. An overview on niosome as carrier in dermal drug delivery.J. Pharm. Sci. Res.2015711923927
     [Google Scholar]
  30. MoghassemiS. HadjizadehA. Nano-niosomes as nanoscale drug delivery systems: An illustrated review.J. Control. Release2014185223610.1016/j.jconrel.2014.04.01524747765
     [Google Scholar]
  31. SankhyanA. PawarP. Recent Trends in Niosome as Vesicular DrugDelivery System.J. Appl. Pharm. Sci.2012203210.7324/JAPS.2012.2625
     [Google Scholar]
  32. RogersonA. CummingsJ. WillmottN. FlorenceA.T. The distribution of doxorubicin in mice following administration in niosomes.J. Pharm. Pharmacol.198840533734210.1111/j.2042‑7158.1988.tb05263.x2899629
     [Google Scholar]
  33. MayerL.D. BallyM.B. HopeM.J. CullisP.R. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential.Biochim. Biophys. Acta Biomembr.1985816229430210.1016/0005‑2736(85)90497‑33839135
     [Google Scholar]
  34. SinghG. DwivediH. SarafS.K. SarafS.A. Niosomal delivery of isoniazid-development and characterization.Trop. J. Pharm. Res.201110210.4314/tjpr.v10i2.66564
     [Google Scholar]
  35. LohumiA. A novel drug delivery system: Niosomes review.J. Drug Deliv. Ther.20122510.22270/jddt.v2i5.274
     [Google Scholar]
  36. MadhavN.V. SainiA. Niosomes: A novel drug delivery system.Int. J. Res. Pharm. Chem.201113498511
     [Google Scholar]
  37. NaikN. ChoukseyS. Niosome: A promising pharmaceutical drug delivery.Int. J. Pharmaceut. Drug Anal.201425
     [Google Scholar]
  38. ShakyaV. BansalB.K. Niosomes: A novel trend in drug delivery.Int. J. Res. Develop. Pharm. Life Sci.20143410361041
     [Google Scholar]
  39. MandalK.M. Niosome: A future of targeted drug delivery systems.J. Adv. Pharmaceut. Technol. Res.20101410.4103/0110‑5558.76435
     [Google Scholar]
  40. KeshavJ. Niosomes as apotential carrier system: A review.Int. J. Pharm. Chem. Biol. Sci.201554
     [Google Scholar]
  41. SarkerA. ShimuI.J. AlamS.A. Niosome: As dermal drug delivery tool.IOSR J. Pharm. Biol. Sci.20151027379
     [Google Scholar]
  42. NasirA. HarikumarS.L. AmanpreetK. Niosomes: An excellent tool for drug delivery.Int. J. Res. Pharm. Chem.201222479487
     [Google Scholar]
  43. RaneB.R. PatilR.S. JainA.S. Formulation development and evaluation of nanogel loaded with montelukast sodium niosomes.Int. J. Pharm. Sci. Res.20211284208422110.13040/IJPSR.0975‑8232.12(8).4208‑21
     [Google Scholar]
  44. TangriP. KhuranaS. Niosomes: Formulation and evaluation.Int. J.201122297499
     [Google Scholar]
  45. KumariR. VermaK. VermaA. YadavG.K. MauryaS.D. Proniosomes: A key to improved drug delivery.J. Drug Deliv. Ther.201400566510.22270/jddt.v0i0.875
     [Google Scholar]
  46. KaurD. KumarS. Niosomes: Present scenario and future aspects.J. Drug Deliv. Ther.201885354310.22270/jddt.v8i5.1886
     [Google Scholar]
  47. SumaU.S. ParthibanS. Senthil KumarG.P. Tamiz ManiT. Novelty of niosomal gel in tdds application.Asian J. Res. Biol. Pharma. Sci.2015324148
     [Google Scholar]
  48. SrivastavaN.S. ThakurS. KaurJ. Niosomes: A novel approach for topical delivery of drugs.2016Available from:https://www.semanticscholar.org/paper/NIOSOMES%3A-A-NOVEL-APPROACH-FOR-TOPICAL-DELIVERY-OF/92968d790a887e7b21c4fac99b8ef22c5531910f(accessed on 12-11-2024).
  49. AlkilaniA. McCruddenM.T. DonnellyR. Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum.Pharmaceutics20157443847010.3390/pharmaceutics704043826506371
     [Google Scholar]
  50. DabkowskaA.P. BarlowD.J. CampbellR.A. HughesA.V. QuinnP.J. LawrenceM.J. Effect of helper lipids on the interaction of DNA with cationic lipid monolayers studied by specular neutron reflection.Biomacromolecules20121382391240110.1021/bm300639n22724519
     [Google Scholar]
  51. MochizukiS. KanegaeN. NishinaK. KamikawaY. KoiwaiK. MasunagaH. SakuraiK. The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine.Biochim. Biophys. Acta Biomembr.20131828241241810.1016/j.bbamem.2012.10.01723092705
     [Google Scholar]
  52. MusielakE. Feliczak-GuzikA. NowakI. Synthesis and potential applications of lipid nanoparticles in medicine.Materials (Basel)202215268210.3390/ma1502068235057398
     [Google Scholar]
  53. JacobS. NairA.B. ShahJ. SreeharshaN. GuptaS. ShinuP. Emerging role of hydrogels in drug delivery systems, tissue engineering and wound management.Pharmaceutics202113335710.3390/pharmaceutics1303035733800402
     [Google Scholar]
  54. SouzaJ.G. GelfusoG.M. SimãoP.S. BorgesA.C. LopezR.F.V. Iontophoretic transport of zinc phthalocyanine tetrasulfonic acid as a tool to improve drug topical delivery.Anticancer Drugs201122878379310.1097/CAD.0b013e328346897921487287
     [Google Scholar]
  55. TaveiraS.F. NomizoA. LopezR.F.V. Effect of the iontophoresis of a chitosan gel on doxorubicin skin penetration and cytotoxicity.J. Control. Release20091341354010.1016/j.jconrel.2008.11.00219047006
     [Google Scholar]
  56. NairA. VyasH. ShahJ. KumarA. Effect of permeation enhancers on the iontophoretic transport of metoprolol tartrate and the drug retention in skin.Drug Deliv.2011181192510.3109/10717544.2010.50936120726811
     [Google Scholar]
  57. CoscoD. PaolinoD. MuzzalupoR. CeliaC. CitraroR. CaponioD. PicciN. FrestaM. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil.Biomed. Microdevices20091151115112510.1007/s10544‑009‑9328‑219507033
     [Google Scholar]
  58. RajeraR. NagpalK. SinghS.K. MishraD.N. Niosomes: A controlled and novel drug delivery system.Biol. Pharm. Bull.201134794595310.1248/bpb.34.94521719996
     [Google Scholar]
  59. ChinembiriT.N. GerberM. Du PlessisL.H. Du PreezJ.L. HammanJ.H. Du Plessi AlcantarN. WilliamsE.C. ToomeyR. Topical delivery of Withania somnifera crude extracts in niosomes and solid lipid nanoparticles.Pharmacogn. Mag.201713S3663671
     [Google Scholar]
  60. CandidoT.Z. de PaivaR.E.F. FigueiredoM.C. de Oliveira CoserL. FrajácomoS.C.L. AbbehausenC. CardinalliI.A. LustriW.R. CarvalhoJ.E. RuizA.L.T.G. CorbiP.P. LimaC.S.P. Silver nimesulide complex in bacterial cellulose membranes as an innovative therapeutic method for topical treatment of skin squamous cell carcinoma.Pharmaceutics202214246210.3390/pharmaceutics1402046235214194
     [Google Scholar]
  61. BhattacharyaS. PrajapatiB.G. Formulation, design and development of niosome based topical gel for skin cancer.Med Clin Res.201723123
     [Google Scholar]
  62. ShahH.S. GotechaA. JethaD. RajputA. BariyaA. PanchalS. ButaniS. Gamma oryzanol niosomal gel for skin cancer: Formulation and optimization using quality by design (QbD) approach.AAPS Open202171910.1186/s41120‑021‑00041‑2
     [Google Scholar]
  63. ChermahiniS.H. NajafiR.B. Niosome encapsulated fluorouracil as drug delivery system to basal-cell skin Cancer.J. Nanosci. Nanomed.2019314
     [Google Scholar]
  64. Al-mahallawiA.M. FaresA.R. Abd-ElsalamW.H. Enhanced permeation of methotrexate via loading into ultra-permeable niosomal vesicles: fabrication, statistical optimization, ex-vivo studies, and in vivo skin deposition and tolerability.AAPS PharmSciTech201920517110.1208/s12249‑019‑1380‑531004239
     [Google Scholar]
  65. RajkumarJ. Venkata RadhaG. Topical drug delivery of 5-fluorouracil proniosomal gel for the treatment of skin cancer: In vitro and in vivo evaluation.Pharmaceut. Sci. Asia202148214716310.29090/psa.2021.02.20.002
     [Google Scholar]
  66. FahmyS.A. RamzyA. SawyA.M. NabilM. GadM.Z. El-ShazlyM. Aboul-SoudM.A.M. AzzazyH.M.E.S. Ozonated olive oil: Enhanced cutaneous delivery via niosomal nanovesicles for melanoma treatment.Antioxidants2022117131810.3390/antiox1107131835883809
     [Google Scholar]
  67. OommenE. ShenoyB.D. UdupaN. KamathR. DeviP.U. Antitumour efficacy of cyclodextrin-complexed and niosome- encapsulated plumbagin in mice bearing melanoma B16F1.Pharm. Pharmacol. Commun.19995428128510.1211/146080899128734857
     [Google Scholar]
  68. AttiaH.H. ShakerD.S. ElMeshadA. El-KayalM. Optimization and in-vitro assessment of the effectiveness of carvedilol-loaded proniosomal gels as a promising therapeutic approach for the topical treatment of skin cancer.J. Drug Deliv. Sci. Technol.20238610466510.1016/j.jddst.2023.104665
     [Google Scholar]
  69. GuptaD.K. AqilM. AhadA. ImamS.S. WaheedA. QadirA. IqubalM.K. SultanaY. Tailoring of berberine loaded transniosomes for the management of skin cancer in mice.J. Drug Deliv. Sci. Technol.20206010205110.1016/j.jddst.2020.102051
     [Google Scholar]
  70. AlcantarN. WilliamsE.C. ToomeyR. Niosome-hydrogel drug delivery system.Patent US 12/622693, 2010
  71. SmithG. ShenoyD.B. LeeR.W. Adjuvant and vaccine compositions.Patent US 12/280099, 2010.
  72. AlcantarN. DearbornK. VanAukerM. ToomeyR. HoodE. Niosome-hydrogel drug delivery.Patent US 11/737,271, 2008.
  73. AwasthiR. KumarS.T. KulkarniG. Frontier lipid-based carrier systems for drug targeting: A laconic review on niosomes.Pharm. Nanotechnol.20142311612810.2174/2211738503666150107234904
     [Google Scholar]
  74. HoodE. GonzalezM. PlaasA. StromJ. VanAukerM. Immuno- targeting of nonionic surfactant vesicles to inflammation.Int. J. Pharm.20073391-222223010.1016/j.ijpharm.2006.12.04817448616
     [Google Scholar]
  75. YangC.C. LeY.C. LiuC.C. Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods.Patent US 10/828700, 2005.
/content/journals/cnanom/10.2174/0124681873335092250115022230
Loading
Niosomes: A Revolutionary Approach for Skin Cancer Treatment
Curr Nanomed 15, 624 (2025); https://doi.org/10.2174/0124681873335092250115022230
/content/journals/cnanom/10.2174/0124681873335092250115022230
/content/journals/cnanom/10.2174/0124681873335092250115022230
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): carcinomas; melanoma; niosome; Skin cancer; topical drug delivery, basal cell carcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test